WSCM
DNLI icon

Wellington Shields Capital Management’s Denali Therapeutics DNLI Stock Holding History

Wellington Shields Capital Management’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-55,400
Closed -$1.34M – 226
2020
Q2 		$1.34M Buy
+55,400
New +$1.3M 0.22% 88

Other funds holding DNLI

CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Shields Capital Management's DNLI Position: Q3 2020 in Review

Wellington Shields Capital Management sold out of Denali Therapeutics (DNLI) in Q3 2020, closing a stake of 55,400 shares — an estimated $1.34M sold.

Wellington Shields Capital Management first reported a position in DNLI in Q2 2020 and held it in 1 quarter. The position peaked at $1.34M in Q2 2020. 170 funds tracked by Wall St. Rank hold DNLI as of Q3 2020.

  • Wellington Shields Capital Management reported no remaining Denali Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Wellington Shields Capital Management sold 55,400 Denali Therapeutics shares in Q3 2020, an estimated $1.34M.
  • Wellington Shields Capital Management first reported a position in Denali Therapeutics in Q2 2020 and held it in 1 quarter.
  • Wellington Shields Capital Management's Denali Therapeutics position peaked at $1.34M in Q2 2020.
  • 170 funds tracked by Wall St. Rank held Denali Therapeutics as of Q3 2020.

Based on Wellington Shields Capital Management's 13F filing for Q3 2020, filed 10 Nov 2020.